NCT03977090

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Phase Ib Clinical Trial of Geptanolimab Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (estimated)
• Sponsor: Genor Biopharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate the pharmacokinetic characteristics of GB226 in combined therapy, evaluate immunogenicity of GB226, and explore the antitumor activity of GB226 in combination with fruquintinib in the treatment of mCRC.

Conditions

• Metastatic Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Geptanolimab Injection	GB226 3mg/kg, q2w, iv.
DRUG	Fruquintinib	Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off

Timeline

• Start date: 2019-04-04
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2019-06-06
• Last updated: 2021-02-10

Locations

1 site across 1 country: China